The anti-diabetic potential of Diabetinol was tested in an animal model and in a pilot study in humans. Male Syrian golden hamsters (n = 18) were fed regular chow, 60% fructose or a 60% fructose diet + 1% Diabetinol. Hamsters fed 60% fructose + 1% Diabetinol demonstrated a decrease in blood glucose, serum insulin, total cholesterol and triacylglycerol levels as compared to the fructose-fed animals. Efficacy of Diabetinol (2 · 525 mg/day) was investigated in a randomized, placebo-controlled, double-blind trial where subjects (n = 19) with impaired fasting glucose (IFG) on either Diabetinol or placebo were presented with a standard oral glucose challenge. After 84 days of supplementation a significant reduction (p < 0.01) in glucose intolerance, total cholesterol, LDL-cholesterol and decreasing trends in the HbA1c were observed in subjects supplemented with Diabetinol. This study demonstrated an important future role for the Diabetinol in glycemic control and management of risk factors in subjects with IFG on oral medication.
Judy-et-al.-2010-Efficacy-of-DiabetinolTM-on-glycemic-control-in-insulin-resistant-hamsters-and-subjects-with-impaired-fasting-glucose-–-a-pilot-study